INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 40 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $778,000,000 | -20.4% | 1,000,000 | 0.0% | 0.01% | -31.2% |
| Q2 2017 | $978,000,000 | +4.4% | 1,000,000 | 0.0% | 0.02% | 0.0% |
| Q1 2017 | $937,000,000 | +4.6% | 1,000,000 | 0.0% | 0.02% | -5.9% |
| Q4 2016 | $896,000,000 | – | 1,000,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Worth Venture Partners, LLC | 1,695,000 | $1,518,000 | 1.26% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 36,000,000 | $31,598,000 | 1.11% |
| DLD Asset Management, LP | 10,000,000 | $8,794,000 | 0.66% |
| TENOR CAPITAL MANAGEMENT Co., L.P. | 12,330,000 | $11,037,000 | 0.66% |
| Castle Creek Arbitrage, LLC | 6,500,000 | $5,706,000 | 0.61% |
| Opera Trading Capital | 3,500,000 | $3,068,000 | 0.49% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 25,100,000 | $21,948,000 | 0.46% |
| Graham Capital Management, L.P. | 13,636,000 | $11,946,000 | 0.44% |
| OAKTREE CAPITAL MANAGEMENT LP | 34,470,000 | $30,352,000 | 0.42% |
| Verition Fund Management LLC | 7,762,000 | $6,835,000 | 0.42% |